Figure. S1. Trans MAM-6 inhibits a mutant GABA A R after conjugation. Table S1 . The GABA sensitivity of untreated and MAM-6 treated α1-mutants. 
. PTL treatment does not confer light sensitivity onto endogenous channels in hippocampal neurons.
(A) MAB-0 treatment does not photosensitize endogenous GABA A Rs in cultured hippocampal neurons. Average mIPSC traces from a representative neuron are shown. I 500 /I 380 = 1.00 ± 0.02 (V hold = -60 mV; n = 3, P = 0.87).
(B) MAB-0 treatment does not photosensitize endogenous glutamate receptors in cultured hippocampal neurons. Average mEPSC traces from a representative neuron are shown. I 500 /I 380 = 0.97 ± 0.10 (V hold = -70 mV; n = 4, P = 0.64).
(C) MAB-0 treatment does not photosensitize endogenous AMPARs in a hippocampal slice. Evoked EPSC traces from a CA1 pyramidal neuron are shown. I 500 /I 380 = 1.02 ± 0.01 (V hold = -70 mV; n = 4, P = 0.2).
(D) MAB-0 treatment does not photosensitize endogenous NMDARs in a hippocampal slice. Evoked EPSC traces from a CA1 pyramidal neuron are shown. Currents were measured 100 ms after the stimulus. I 500 /I 380 = 0.95 ± 0.04 (V hold = +40 mV; n = 3, P = 0.3).
(E) MAB-0 treatment does not photosensitize endogenous voltage-gated Na + channels. Inward currents (elicited by a 200-ms depolarization to -10 mV) from a representative neuron are shown. I 500 /I 380 = 0.99 ± 0.05 (V hold = -70 mV; n = 4, P = 0.87). a. Current ratio was measured at 3 µM GABA (500 nm vs. 380 nm).
b. The effect of MAM-6 attachment or cysteine substitution on receptor function was evaluated by the change of current ratio at 3 µM vs. 3 mM GABA. As a reference, EC 50 of the wild-type α1β2 is ~3 µM (first row).
c. The untreated receptor's sensitivity to GABA is lower than that of the wild-type (indicated by I 3µM /I 3mM ).
d. The receptor's sensitivity to GABA is reduced in both 500-nm and 380-nm lights after MAM-6 attachment.
e. The untreated receptor's sensitivity to GABA is the same as that of the wild-type. The receptor's sensitivity to GABA is unaltered in 380-nm light after MAM-6 attachment. These features make α1(T125C) the best mutant for neurophysiological applications.
B. Synthesis of MAM-6, MAB-6, MAM-0, and MAB-0
Scheme S1.
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Scheme S2.
 General Methods
All reagents and solvents were purchased through Fisher Scientific. All reactions involving air-and moisture-sensitive reagents were performed under an argon atmosphere using syringe-septum cap techniques. DMF and CH 2 Cl 2 were dried by storing over molecular sieves (4 Å ). THF was distilled from sodium/benzophenone. Analytical thin-layer chromatography (TLC) was carried out using Merck Silica gel 60 F254 aluminum sheets. Compounds were detected as single spots on TLC plates and visualized using UV light (254 or 366 nm) and KMnO 4 or ninhydrin. Merck silica gel (35-70 mesh) was used for flash chromatography.
1 H NMR spectra were recorded on a 400 MHz Bruker NMR spectrometer using the residual proton resonance of the solvent as the standard. Chemical shifts are reported in parts per million (ppm). When peak multiplicities are given, the following abbreviations are used: s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet.
13 C NMR spectra were proton decoupled and recorded on a 100 MHz spectrometer using carbon signal of the deuterated solvent as the internal standard. Mass spectra were measured either on a Waters ZQ device for LRMS or at the Notre Dame Mass Spectrometry facility microTOF for HRMS.
tert-butyl-4-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetamido)phenylcarbamate (2): Maleimide 1 (2.0 g, 13 mmol) was dissolved in anhydrous CH 2 Cl 2 (30 mL), treated with oxalyl chloride (4.8 g, 39 mmol), and DMF (1 drop) at ambient temperature under nitrogen. After 4 h of stirring at room temperature, the solvent was evaporated under reduced pressure, the residue dissolved in anhydrous THF, and added drop wise over a period of 30 min to a stirred suspension of tert-butyl-4-aminophenylcarbamate (2.48 g, 12 mmol) and triethylamine (1.2 g, 12 mmol) at 0 o C. After completion of addition, the reaction mixture was brought to ambient temperature and stirred for an additional 4 h. The solvent was evaporated under reduced pressure and dissolved in EtOAc (50 mL), washed with aq. NaHCO 3 , and brine. The extract was dried with anhydrous Na 2 SO 4 , evaporated, and recrystallized from ethanol to obtain compound 2 (3.4 g, 81% 
6 mmol) was dissolved in 5% TFA in CH 2 Cl 2 (50 mL) and stirred at room temperature for 2 h. The reaction mixture was evaporated and dried under reduced pressure to obtain compound 3 (2.0 g, 98%). tert-butyl-3-(4-nitrophenyl)propanoate (5): 3-(4-Nitrophenyl)propanoic acid 4 (5.0 g, 25.6 mmol), tertbutanol (1.88 g, 25.6 mmol), and tributylamine (14.8 mL, 62.2 mmol) were dissolved in toluene (100 mL) and added to a suspension of 2-chloro-1-methylpyridinium iodide (7.84 g, 30.6 mmol) in toluene (50 mL). The reaction mixture was refluxed overnight. After removal of the solvent, the dark residue was purified by flash column chromatography (EtOAc/hexane 1:3) to obtain tert-butyl-3-(4-nitrophenyl)propanoate 5 (4.20 g, 84 %) as light yellow solid. 
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tert-butyl-3-(4-nitrosophenyl)propanoate (6):
Tert-butyl-3-(4-nitrophenyl)propanoate (4.18 g, 17.2 mmol) was dissolved in 2-methoxyethanol (200 mL) and to this mixture was added a solution of NH 4 Cl (1.36 g, 25.42 mmol) in H 2 O (60 mL). The reaction mixture was thoroughly degassed by bubbling a stream of argon through the reaction mixture for approximately 30 min. Zn dust (3.7 g, 56.6 mmol) was added to the solution very slowly. The reaction mixture was stirred for 6 h at room temperature, filtered, and slowly added to a solution of FeCl 3: 6H 2 O (9.28 g, 36.3 mmol) in a 2:1 mixture of H 2 O and EtOH at -10 °C. After 1 h the mixture was allowed to warm to room temperature and stirred for another hour. The mixture was extracted with EtOAc (3 x 100 mL) and dried with anhydrous Na 2 SO 4 . The solvent was evaporated to obtain an oil that was purified by flash chromatography (EtOAc /hexane 1:3) to afford compound 6 (3.34 g) as a dark green oil that was used without further purification.
tert-butyl-3-{4-[(E)-2-{4-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetamido]phenyl}diazen-1-yl]phenyl}propanoate (7):
A solution of compound 6 (3.0 g, 13.2 mmol) in glacial acetic acid (125 mL) was added to a solution of compound 3 (3.36 g, 13.2 mmol) in glacial acetic acid (125 mL) and stirred for 48 h at room temperature. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography (EtOAc/hexane 1:1) to obtain compound 7 (3.14 g, 51%) as an orange solid. 
3-(4-{4-[2-(2,5-Dioxo-2,5-dihydro-pyrrol-1-yl)-acetylamino]-phenylazo}-phenyl)-propionic acid (8):
To a solution of compound 7 (2.74 g, 5.93 mmol) in CH 2 Cl 2 (300 mL) was added TFA (30 mL). After stirring for 24 h at room temperature, water (30 mL) was added and the organic layer was separated and washed with water and brine. After drying with MgSO 4 , the solvent was removed under reduced pressure to obtain compound 8 (2.35 g, 97%) as an orange-brown solid. 
MAM-0 (15):
Compound 9 (34 mg, 67 µmol) and DIPEA (11 µL, 67 µmol) were added to a solution of muscimol (7.7 mg, 67 µmol) in N-methylpyrrolidinone (1.9 mL). The reaction mixture was stirred at room temperature overnight and quenched with TFA (5.1 µL, 67 µmol). 
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MAB-6 (16):
Compound 9 (0.075 g, 0.14 mmol) and DIPEA (24 µL, 0.14 mmol) were added to a solution of tethered 4-hydroxybenzylamine 12 (35 mg, 0.14 mmol) in N-methylpyrrolidinone (3.0 mL). The reaction mixture was stirred at room temperature overnight and quenched with TFA (11 µL) and diluted with EtOAc (50 mL). To the mixture was added water (40 mL) and extracted with EtOAc (3 x 50 mL), dried (Na 2 SO 4 ), and evaporated. 
MAB-0 (17):
Compound 9 (0.05 g, 0.1 mmol) and 4-hydroxybenzylamine (12.2 mg, 0.1 mmol) were dissolved in anhydrous DMF (1 mL) and treated with triethylamine (42 µL, 0.3 mmol). The reaction mixture was stirred overnight at room temperature. The organic solvent was evaporated and the crude residue was purified by silica gel chromatography (CH The cDNAs of wild-type rat GABA A R α1 (in pGH19), β2 (in pGH19), and γ2S (in pUNIV) were obtained from Professor Cynthia Czajkowski (University of Wisconsin). The genes of α and β subunits were sub-cloned into vector pCDNA3.1 for expression in HEK293T cells. Mutants α1(K70C) and α1(D123C) (in pGH19) were obtained from Professor Cynthia Czajkowski. Other cysteine mutants were prepared by site-directed mutagenesis in the wild-type α1 clones (in pGH19 and pCDNA3.1 for expression in oocytes and HEK293T cells, respectively). Mutations were confirmed by sequencing.
 Construction of pAAV-hSyn-eGFP-2A-myc-α1(T125C)
This bi-cistronic construct was designed to express eGFP and GABA A R α1(T125C) in a 1:1 ratio using the 2A protein sequence (GSGATNFSLLKQAGDVEENPGP) 2 and to restrict gene expression in neurons using a human synapsin promoter. 3 The vector also contains terminal repeats (TR) and woodchuck hepatitis post-transcriptional regulatory element (WPRE) for packaging into the adenoassociated virus (AAV). A myc epitope tag (EQKLISEEDL) was inserted into the N-terminus of α1(T125C) as previously described. 4 The 2A-myc-α1(T125C) fragment was made with primers 5'-TCGATCGGGCCCATGAAGAAAAGTCGGGG-3' and 5'-TCGATCAAGCTTCTATTGATGGGGTGTGGG-3'. The PCR product was digested with ApaI and HindIII to obtain the insert fragment. The eGFP-2A fragment was made via PCR with primers 5'-TCGATCGCTAGCGCTACCGGTCGCCACCATGGTGAGCAAGGGCGAGG-3' and 5'-TCGATCGGGCCCTGGGTTCTCCTCCACGTCTCCAGCCTGCTTGAGCAGGGAGAAGTTTGTAG CGCCAGATCCCTTGTACAGCTCGTCCATGC-3' followed by digestion with ApaI and NheI. The pAAV vector backbone was digested with NheI and HindIII and then ligated with the 2A-myc-α1(T125C) and eGFP-2A fragments. The final construct was confirmed by sequencing.
 Preparation of Adeno Associated Virus (AAV)
AAV9 encoding GFP-2A-myc-α1(T125C) was produced from transfected HEK293T cells as described previously. 5 After ultracentrifugation, the interphase between the 54% and 40% iodixanol fraction, and the lower three-quarters of the 40% iodixanol fraction were extracted and diluted with an equal volume of phosphate-buffered saline (PBS) plus 0.001% Tween 20. This fraction was then buffer exchanged and concentrated with Amicon Ultra-15 Centrifugal Filter Units to a final volume of ~100 µL. Virus was then titered for DNase-resistant vector genomes by Real-Time qPCR relative to WPRE standards. The resulting titer was 7.5 × 10 12 vg•mL -1 .
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C.2. Electrophysiology
 Two-electrode voltage-clamp Each oocyte was placed in a 0.2-mL perfusion chamber, impaled with two glass microelectrodes (1-2.5 MΩ resistance) filled with 3 M KCl, and voltage clamped (at -80 mV) with an OC-725C amplifier (Warner Instruments) in OR1 solution containing (in mM): 96 NaCl, 2 KCl, 1.8 CaCl 2 , 1 MgCl 2 , and 5 HEPES; pH 7.4. Drug perfusion, data acquisition, and analysis were carried out with Clampex software through a Digidata 1200 interface (Molecular Devices). Light switching was carried out by a Lambda DG-4 (Sutter Instruments) using 383 nm and 497 nm filters.
 Whole-cell voltage-clamp (HEK293T cells)
Recordings were carried out at room temperature using pipettes with 2.5-4 MΩ resistance. Cells were held at -70 mV. Pipettes were pulled from filamented borosilicate pipettes (G150TF-3, Sutter Instruments). The extracellular solution contained (in mM): 140 NaCl, 5 KCl, 1 MgCl 2 , 10 HEPES, 2 CaCl 2 , and 10 glucose; pH 7.4. The intracellular solution contained (in mM): 140 CsCl, 4 NaCl, 10 HEPES, 2 MgCl 2 , 2 Mg-ATP, and 10 EGTA; pH 7.2. Signals were amplified using a Patch Clamp PC-501A amplifier (Warner Instruments), low-pass filtered at 2 kHz, digitized at 10 kHz by a Digidata 1322A converter (Molecular Devices), and acquired with software Clampex 10 (Molecular Devices). Illumination for PTL photoisomerization was provided by a Lambda-LS xenon lamp (Sutter Instruments) with 379 ± 17 nm and 500 ± 8 nm band pass filters. Recordings were performed at room temperature using the same pipette and instrument settings as those for HEK293T recordings. To record miniature IPSCs, cells were held at -60 mV. The extracellular solution contained (in mM): 138 NaCl, 1.5 KCl, 1.2 MgCl 2 , 2.5 CaCl 2 , 5 HEPES, 10 Glucose, 0.025 DNQX, 0.05 APV, and 0.0005 TTX; pH 7.4. The internal solution contained (in mM): 140 CsCl, 4 NaCl, 2 MgCl 2 , 10 HEPES, 10 EGTA, and 2 Mg-ATP; pH 7.2. To record miniature EPSCs, cells were held at -70 mV. The extracellular solution contained (in mM): 138 NaCl, 1.5 KCl, 1.2 MgCl 2 , 2.5 CaCl 2 , 5 HEPES, 10 Glucose, 0.001 TTX, and 0.02 bicuculline; pH 7.4. The intracellular solution contained (in mM): 8 NaCl, 135 K-gluconate, 4 MgCl 2 , 10 HEPES, 2 Mg-ATP, and 1 EGTA; pH 7.4. All miniature events were analyzed using the MiniAnalysis software (Synaptosoft). The event detection threshold was set at 5 fold of the root-mean-square noise level, which typically was 2-5 pA. The detected events were further visually verified prior to statistical analysis. For each light condition, a total of 50-380 events were pooled for analysis.
The extracellular solution for recording voltage-gated currents contained (in mM): 138 NaCl, 1.5 KCl, 1.2 MgCl 2 , 2.5 CaCl 2 , 5 HEPES, 10 Glucose, 0.02 biccuculine, 0.025 DNQX, and 0.05 APV; pH 7.4. The intracellular solution contained (in mM): 10 NaCl, 135 K-gluconate, 2 MgCl 2 , 10 HEPES, 1 EGTA, and 2 Mg-ATP; pH 7.4. Cells were held at -70 mV and stepped for 200 ms to -10 mV (Na + channels) or +40 mV (K + channels).
